Anzeige
Mehr »
Freitag, 09.05.2025 - Börsentäglich über 12.000 News
Rallye naht! Die Wette eines Milliardärs auf die Zukunft des Kupfers...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ERT8 | ISIN: US45333F1093 | Ticker-Symbol:
NASDAQ
08.05.25 | 21:58
0,113 US-Dollar
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
INCANNEX HEALTHCARE INC Chart 1 Jahr
5-Tage-Chart
INCANNEX HEALTHCARE INC 5-Tage-Chart

Aktuelle News zur INCANNEX HEALTHCARE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
25.04.Incannex Healthcare Inc. - 8-K, Current Report1
INCANNEX HEALTHCARE Aktie jetzt für 0€ handeln
16.04.Incannex Healthcare Inc. - S-1/A, General form for registration of securities3
03.04.Incannex Healthcare Inc. - 8-K, Current Report5
03.04.Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)157NEW YORK and MELBOURNE, Australia, April 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing...
► Artikel lesen
24.03.Incannex Healthcare files to sell 65.97M shares of common stock for holders1
18.03.Incannex Healthcare Inc. - 8-K, Current Report-
10.03.Incannex Healthcare Inc. - 8-K, Current Report-
07.03.Incannex Healthcare prices $12.5M private placement1
07.03.Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules1
14.02.Incannex Healthcare Limited Loss At -$5.8 Mln In Q22
14.02.Incannex Healthcare Limited Loss At -$5.89 Mln In Q21
14.02.Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates231Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew OSA Clinical Advisory Board Announced; Appoints Dr....
► Artikel lesen
14.02.Incannex Healthcare Inc. - 8-K, Current Report-
14.02.Incannex Healthcare Inc. - 10-Q, Quarterly Report-
04.02.Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board1
04.02.Incannex Healthcare Inc. - 8-K, Current Report-
23.01.Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea122Demonstrated bioavailability of IHL-42X, Incannex's proprietary combination formulation, confirming delivery of both dronabinol and acetazolamideAchieved similar PK and equivalent total drug exposure...
► Artikel lesen
23.01.Incannex Healthcare Inc. - 8-K, Current Report-
10.01.Incannex Healthcare Inc. - 8-K, Current Report1
11.12.24Incannex Healthcare Inc. - 8-K, Current Report-
Seite:  Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1